Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

91
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
91
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.2K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.2K
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

96
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
96
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.6K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.6K
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

103
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
103
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

100
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
100

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development and validation of a risk assessment model for hospital-acquired venous thrombosis in medical in-patients with cancer.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Oral Anticoagulants and Risk of Bleeding and Death in Cancer-Associated Venous Thromboembolism.

JACC. Advances·2026
Same author

Maternal age and pregnancy-related cardiovascular complications.

Nature communications·2026
Same author

Possible Diagnostic Error in Cervical Artery Dissection: Analysis of STOP-CAD Study.

Journal of the American Heart Association·2026
Same author

Mechanism-informed evaluation of particle formation in high-concentration monoclonal antibodies during fill-finish: Impact of pump materials, surface interactions, and system architecture.

Journal of pharmaceutical sciences·2026
Same author

Life's Essential 8 and Risk of Severe COVID-19 Among Adults Without Clinical Cardiovascular Disease: The C4R Study.

Journal of the American Heart Association·2026

Related Experiment Video

Updated: Nov 8, 2025

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
06:01

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

Published on: August 18, 2015

15.1K

Thrombophilia Testing After Ischemic Stroke: Why, When, and What?

Setareh Salehi Omran1, Adam Hartman1, Neil A Zakai2

  • 1Department of Neurology, University of Colorado School of Medicine, Aurora (S.S.O., A.H.).

Stroke
|April 20, 2021
PubMed
Summary

Thrombophilia testing after ischemic stroke is often uncertain. Antiphospholipid syndrome is a key risk factor, especially in young patients, suggesting targeted testing in specific cases.

More Related Videos

Prehospital Thrombolysis: A Manual from Berlin
05:52

Prehospital Thrombolysis: A Manual from Berlin

Published on: November 26, 2013

22.1K
A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

3.1K

Related Experiment Videos

Last Updated: Nov 8, 2025

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
06:01

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

Published on: August 18, 2015

15.1K
Prehospital Thrombolysis: A Manual from Berlin
05:52

Prehospital Thrombolysis: A Manual from Berlin

Published on: November 26, 2013

22.1K
A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

3.1K

Area of Science:

  • Neurology
  • Hematology
  • Genetics

Background:

  • Thrombophilia testing is common after ischemic stroke, especially cryptogenic strokes.
  • Evidence linking most thrombophilias to ischemic stroke is limited, creating diagnostic uncertainty.
  • Antiphospholipid syndrome (APS) is an acquired thrombophilia with a notable association with arterial thromboembolism.

Purpose of the Study:

  • To review and contextualize data on thrombophilic conditions in ischemic stroke patients.
  • To assess the risks, predictors, and outcomes associated with thrombophilias in ischemic stroke.
  • To evaluate the rationale and utility of thrombophilia testing in stroke management.

Main Methods:

  • Topical review of existing literature on thrombophilia and ischemic stroke.
  • Analysis of data regarding inherited and acquired thrombophilias.
  • Contextualization of findings within clinical stroke scenarios.

Main Results:

  • Inherited thrombophilias show an uncertain association with ischemic stroke risk.
  • Antiphospholipid syndrome is identified as a significant risk factor for ischemic stroke, particularly in younger individuals.
  • Testing may be warranted in specific situations like stroke in the young, cryptogenic stroke, and high estrogen states.

Conclusions:

  • The utility of routine thrombophilia testing post-ischemic stroke requires further investigation.
  • Targeted thrombophilia testing may be beneficial in select patient populations and clinical contexts.
  • Future research should focus on prospective studies evaluating testing utility, cost-effectiveness, and optimal secondary prevention strategies.